drugset
drugset / Trial / NCT02448368

RDEA3170 Tablet and Capsule Bioavailability Study

NCT02448368 ↗

Phase 1 Completed 35 enrolled Ardea Biosciences, Inc.
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to determine the relative bioavailability of RDEA3170 capsules compared with RDEA3170 tablets.

Timeline

Start
2015-05-01
Primary completion
2015-06-26
Completion
2016-01-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Verinurad Small molecule 2.5 mg —
Subject Verinurad Small molecule 5 mg —
Subject Verinurad Small molecule 10 mg —

Indications

No indication recorded.